**Table S1:** *In Vitro* Antiviral Activity of PF-3450074 Against Different HIV-1 Clinical Isolates or Laboratory Strains in PBMCs. Supplementary to Figure 1, the properties of the various isolates tested (represented by single points) against the compound are shown.

<table>
<thead>
<tr>
<th>HIV-1 Isolate</th>
<th>Clade&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Receptor</th>
<th>EC&lt;sub&gt;50&lt;/sub&gt; (µM)</th>
<th>TI&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>NL4-3</td>
<td>B</td>
<td>X4</td>
<td>0.64 ± 0.10</td>
<td>&gt; 16</td>
</tr>
<tr>
<td>BaL</td>
<td>B</td>
<td>R5</td>
<td>0.26 ± 0.08</td>
<td>&gt; 38</td>
</tr>
<tr>
<td>SF162</td>
<td>B</td>
<td>R5</td>
<td>0.25 ± 0.11</td>
<td>&gt; 40</td>
</tr>
<tr>
<td>92HT599</td>
<td>B</td>
<td>R5/X4</td>
<td>0.08 (0.04, 0.12)</td>
<td>&gt; 25</td>
</tr>
<tr>
<td>92HT596</td>
<td>B</td>
<td>R5/X4</td>
<td>0.25 (0.38, 0.12)</td>
<td>&gt; 26</td>
</tr>
<tr>
<td>92BR004</td>
<td>B</td>
<td>R5</td>
<td>0.19 (0.34, 0.04)</td>
<td>&gt; 29</td>
</tr>
<tr>
<td>92UG037</td>
<td>A</td>
<td>R5</td>
<td>0.32 ± 0.18</td>
<td>&gt; 32</td>
</tr>
<tr>
<td>94UG118</td>
<td>D</td>
<td>R5</td>
<td>0.23 (0.14, 0.33)</td>
<td>&gt; 31</td>
</tr>
<tr>
<td>97ZA003</td>
<td>C</td>
<td>R5</td>
<td>0.20 (0.19, 0.21)</td>
<td>&gt; 47</td>
</tr>
<tr>
<td>CMU06</td>
<td>E</td>
<td>X4</td>
<td>0.14 (0.16, 0.12)</td>
<td>&gt; 61</td>
</tr>
</tbody>
</table>

<sup>a</sup>Antiviral activity was determined by measuring RT activity 7 days after infection of PBMCs with HIV-1 clinical isolates (X4, CXCR4; R5, CCR5).

<sup>b</sup>Clade and receptor assignments based on designations from the NIH AIDS Research and Reference Reagent Program or our collaborator for the study (SRI).

<sup>c</sup>TI, therapeutic index calculated by dividing the mean EC<sub>50</sub> value into the mean CC<sub>50</sub> value determined in PBMCs (>10 microM).